TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, ther...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Tenshin, Hirofumi, Teramachi, Jumpei, Oda, Asuka, Amachi, Ryota, Hiasa, Masahiro, Bat-Erdene, Ariunzaya, Watanabe, Keiichiro, Iwasa, Masami, Harada, Takeshi, Fujii, Shiro, Kagawa, Kumiko, Sogabe, Kimiko, Nakamura, Shingen, Miki, Hirokazu, Kurahashi, Kiyoe, Yoshida, Sumiko, Aihara, Kenichi, Endo, Itsuro, Tanaka, Eiji, Matsumoto, Toshio, Abe, Masahiro
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2017
Schlagworte:
Immunobiology and Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737122/
https://ncbi.nlm.nih.gov/pubmed/29296860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017008813
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge